Wealth Enhancement Advisory Services LLC Has $706,000 Stake in Chemed Co. (NYSE:CHE)

Wealth Enhancement Advisory Services LLC grew its stake in Chemed Co. (NYSE:CHE) by 6.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,175 shares of the company’s stock after buying an additional 75 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Chemed were worth $706,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Kayne Anderson Rudnick Investment Management LLC raised its stake in shares of Chemed by 2.6% in the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 580,316 shares of the company’s stock valued at $314,868,000 after acquiring an additional 14,651 shares in the last quarter. William Blair Investment Management LLC grew its holdings in Chemed by 2.7% during the second quarter. William Blair Investment Management LLC now owns 475,372 shares of the company’s stock valued at $257,927,000 after purchasing an additional 12,705 shares during the last quarter. Impax Asset Management Group plc grew its holdings in Chemed by 19.5% during the second quarter. Impax Asset Management Group plc now owns 317,943 shares of the company’s stock valued at $172,510,000 after purchasing an additional 51,974 shares during the last quarter. TD Asset Management Inc raised its position in shares of Chemed by 10.9% in the second quarter. TD Asset Management Inc now owns 282,753 shares of the company’s stock valued at $153,416,000 after purchasing an additional 27,800 shares during the period. Finally, Epoch Investment Partners Inc. lifted its stake in shares of Chemed by 22.1% in the second quarter. Epoch Investment Partners Inc. now owns 223,134 shares of the company’s stock worth $121,068,000 after buying an additional 40,358 shares during the last quarter. Institutional investors and hedge funds own 95.85% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Royal Bank of Canada lowered their target price on shares of Chemed from $697.00 to $633.00 and set an “outperform” rating on the stock in a research note on Tuesday.

Insider Activity

In related news, CEO Kevin J. Mcnamara sold 2,000 shares of Chemed stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $598.81, for a total transaction of $1,197,620.00. Following the sale, the chief executive officer now directly owns 103,735 shares of the company’s stock, valued at $62,117,555.35. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $598.81, for a total value of $1,197,620.00. Following the completion of the transaction, the chief executive officer now owns 103,735 shares of the company’s stock, valued at $62,117,555.35. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director George J. Walsh III sold 400 shares of Chemed stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $597.47, for a total value of $238,988.00. Following the sale, the director now directly owns 3,046 shares in the company, valued at $1,819,893.62. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 5,144 shares of company stock valued at $3,002,419. Insiders own 3.32% of the company’s stock.

Chemed Stock Up 3.2 %

CHE opened at $549.99 on Thursday. Chemed Co. has a 12-month low of $523.33 and a 12-month high of $654.62. The firm has a market capitalization of $8.28 billion, a P/E ratio of 27.79, a price-to-earnings-growth ratio of 2.16 and a beta of 0.46. The stock’s 50 day moving average price is $583.24 and its two-hundred day moving average price is $566.63.

Chemed (NYSE:CHE) last announced its earnings results on Tuesday, October 29th. The company reported $5.64 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.76 by ($0.12). Chemed had a return on equity of 27.86% and a net margin of 12.69%. The company had revenue of $606.18 million for the quarter, compared to the consensus estimate of $612.22 million. During the same period last year, the firm posted $5.32 EPS. The company’s revenue was up 7.4% compared to the same quarter last year. As a group, analysts anticipate that Chemed Co. will post 22.41 earnings per share for the current year.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.